APAC Pancreatic Cancer Market was worth USD 0.38 billion in 2019 and estimated to be growing at a CAGR of 8.5 %, to reach USD 0.57 billion by 2024. Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of the pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. It is the ninth leading cause of cancer death in Asia.
Cancer starts when cells in the body begin to grow beyond control. Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice. Apart from lifestyle dependent factors like alcohol consumption, obesity and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer.
Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of the majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Based on the type of treatment, the market has been classified into surgery, chemotherapy, radiation therapy and others. By type, the market has been further segmented as exocrine pancreas cancer and endocrine pancreas cancer. And by end-users as hospitals, clinics, research institutes and others. Furthermore, based on geography the market is segmented into various regions namely Japan, China, India and Australia. Globally North America is the largest market for pancreatic cancer. The prevalence of pancreatic cancer is more in North American countries with U.S. having the highest number of pancreatic cancer patients in the world. Asia-Pacific is anticipated to be the fastest-growing region across the globe.
Key players in the pancreatic cancer market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Treatment
5.1.1 Introduction
5.1.2 Surgery
5.1.3 Chemotherapy
5.1.4 Radiation Therapy
5.1.5 Others
5.1.6 Y-o-Y Growth Analysis, By Type of Treatment
5.1.7 Market Attractiveness Analysis, By Type of Treatment
5.1.8 Market Share Analysis, By Type of Treatment
5.2 Type
5.2.1 Introduction
5.2.2 Exocrine Pancreas Cancer
5.2.3 Endocrine Pancreas Cancer
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 End-users
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Research Institutes
5.3.5 Others
5.3.6 Y-o-Y Growth Analysis, By End-users
5.3.7 Market Attractiveness Analysis, By End-users
5.3.8 Market Share Analysis, By End-users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type of Treatment
6.1.3.3 By Type
6.1.3.4 By End-users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type of Treatment
6.1.4.3 By Type
6.1.4.4 By End-users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type of Treatment
6.1.5.3 By Type
6.1.5.4 By End-users
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Eli Lilly
8.1.1 Overview
8.1.2 Type of Product
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen, Inc.
8.3 Celgene Corp.
8.4 F. Hoffmann-La Roche
8.5 Clovis Oncology Inc.
8.6 Pfizer
8.7 Novartis AG
8.8 Threshold Pharmaceuticals Inc.
8.9 Aduro BioTech Inc.
8.10 Infinity Pharmaceuticals Inc.
8.11 NewLink Genetics Corp.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
